

# PRESS RELEASE

innate pharma

## NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT NOVEMBER 1, 2018

Marseille, France, November 8, 2018, 7:00 AM CET

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (*Autorité des Marchés Financiers*, or "AMF") charter, Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at November 1, 2018:

Total number of shares outstanding:	63,932,655 "A" shares (ordinary shares) 6,931 "B" shares (preferred shares)
Total number of theoretical voting rights (1):	63,932,655
Total number of exercisable voting rights (2):	63,914,180

(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

### About Innate Pharma:


Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma's broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com)



# PRESS RELEASE

**innate pharma**

---

## Information about Innate Pharma shares:

<b>ISIN code</b>	FR0010331421
<b>Ticker code</b>	IPH
<b>LEI</b>	9695002Y8420ZB8HJE29

## Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website [www.amf-france.org](http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

## For additional information, please contact:

### Investors

#### **Innate Pharma**

Dr Markus Metzger / Danielle Spangler /  
Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

### International Media

#### **Consilium Strategic Communications**

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

[InnatePharma@consilium-comms.com](mailto:InnatePharma@consilium-comms.com)

### French Media

#### **ATCG Press**

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

[presse@atcg-partners.com](mailto:presse@atcg-partners.com)